Drug Trial Radar · NCT06762457
A First-in-Human Single and Multiple Ascending Dose Study of MT-501
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Dec 11, 2024
Primary completion
May 22, 2025
Study completion May 22, 2025
Sponsor
- Lead sponsor
- Mirador Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) with Single and Multiple Ascending Oral Doses of MT-501 in Healthy Adults.
Conditions
- Healthy Volunteers
Interventions
MT-501Drug
MT-501 Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome Measure: Number of Subjects with non-SAEs and SAESTime frame: Up to 14 days post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mirador Clinical Department
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.